Special drug use-results surveillance <Patients with cold agglutinin disease>

Special drug use-results surveillance <Patients with cold agglutinin disease> - Special drug use-results surveillance <Patients with cold agglutinin disease>

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000049607

Enrollment

100

Registered

2022-11-25

Start date

2022-11-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cold agglutinin disease

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The target population of interest is patients with CAD treated with sutimlimab, but all patients treated with sutimlimab are included.

Exclusion criteria

Exclusion criteria: NA

Design outcomes

Primary

Measure	Time frame
Safety (Adverse Drug Reaction)	—

Secondary

Measure	Time frame
Efficacy	—

Countries

Japan

Contacts

Public ContactRecordati Rare Diseases Japan K.K. Recordati Rare Diseases Japan K.K.

Recordati Rare Diseases Japan K.K. Post-Marketing Surveillance Department

rrdj_pms@recordati.com03-4510-2910

Outcome results